AstraZeneca stock: growth
AZNAstraZeneca reported $58.74B in revenue for fiscal 2025, up 8.6% on the prior year, up 17.2% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 17.2% | 9.0% | 4.3% |
| Revenue per share | 13.3% | 6.8% | 4.3% |
| Earnings | 26.3% | 13.8% | 2.8% |
| Earnings per share | 22.0% | 11.5% | 2.9% |
| Free cash flow | 31.6% | 32.1% | 1.6% |
| Free cash flow per share | 27.3% | 29.4% | 1.7% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $26.48B | $6.04B | $6.35B |
| 2007 | $29.56B | $5.6B | $5.83B |
| 2008 | $31.6B | $6.1B | $4.7B |
| 2009 | $32.8B | $7.52B | $8.78B |
| 2010 | $33.27B | $8.05B | $8.26B |
| 2011 | $33.59B | $9.92B | $6.52B |
| 2012 | $27.97B | $6.24B | $2.33B |
| 2013 | $25.81B | $2.56B | $5.34B |
| 2014 | $26.55B | $1.23B | $4.31B |
| 2015 | $24.71B | $2.83B | $536M |
| 2016 | $23B | $3.5B | $1.83B |
| 2017 | $22.47B | $3B | $1.96B |
| 2018 | $22.09B | $2.16B | $1.25B |
| 2019 | $24.38B | $1.34B | $509M |
| 2020 | $26.62B | $3.2B | $2.19B |
| 2021 | $37.42B | $112M | $3.76B |
| 2022 | $44.35B | $3.29B | $7.24B |
| 2023 | $45.81B | $5.96B | $6.57B |
| 2024 | $54.07B | $7.04B | $7.28B |
| 2025 | $58.74B | $10.26B | $8.67B |
Revenue by segment
How AstraZeneca PLC makes its money and how that has shifted. Names are as the company reports them.
- Farxiga$8.4B14%
- Tagrisso$7.3B12%
- Imfinzi$6.1B10%
- Ultomiris$4.7B8%
- Calquence$3.5B6%
- Lynparza$3.3B6%
- Other$25.5B43%
“Other” combines smaller and former segments with revenue the company does not assign to a segment. Names as reported, with abbreviations spelled out for the largest companies. The company split earlier years differently. A history would not be comparable, so only 2025 is shown.
Figures as a table
| 2025 | Share 2025 | |
|---|---|---|
| Farxiga | $8.4B | 14.3% |
| Tagrisso | $7.25B | 12.3% |
| Imfinzi | $6.06B | 10.3% |
| Ultomiris | $4.72B | 8% |
| Calquence | $3.52B | 6% |
| Lynparza | $3.28B | 5.6% |
| Other | $25.51B | 43.4% |
| Total revenue | $58.74B | 100% |
Revenue by region
Where AstraZeneca PLC generates its revenue.
- The Americas$27.6B47%
- Europe excluding the United Kingdom$13.5B23%
- Asia, Africa And Australasia$13.4B23%
- United Kingdom$4.4B7%
The company split earlier years differently. A history would not be comparable, so only 2025 is shown.
Figures as a table
| 2025 | Share 2025 | |
|---|---|---|
| The Americas | $27.56B | 46.9% |
| Europe excluding the United Kingdom | $13.46B | 22.9% |
| Asia, Africa And Australasia | $13.37B | 22.8% |
| United Kingdom | $4.36B | 7.4% |
| Total revenue | $58.74B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 15 Oct 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.